Sanofi has filed a patent for recombinant antibodies and fusion proteins that can bind to and inhibit B7-H4, a protein associated with disease. The patent also includes nucleic acid molecules encoding these antibodies and therapeutic compositions. The claim specifies the sequences of the heavy and light chain variable regions of the antibodies. GlobalData’s report on Sanofi gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Sanofi - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Sanofi, NSAID cancer drugs was a key innovation area identified from patents. Sanofi's grant share as of September 2023 was 60%. Grant share is based on the ratio of number of grants to total number of patents.

Recombinant antibodies for inhibiting b7-h4 in disease treatment

Source: United States Patent and Trademark Office (USPTO). Credit: Sanofi

A recently filed patent (Publication Number: US20230312724A1) describes an anti-B7-H4 antibody and its antigen-binding fragment. The antibody consists of a heavy chain variable region and a light chain variable region, each containing three complementarity-determining regions (CDRs). The patent claims various specific sequences for these CDRs, including combinations of SEQ ID NOs: 16, 17, 18, 20, 21, 22, 66, 67, 68, 70, 71, 72, 4, 5, 6, 8, 9, 10, 77, 78, 79, 81, 82, 83, 46, 47, 48, 50, 51, 52, 88, 89, 90, 92, 93, 94, 96, 97, 98, 100, 101, 102, 104, 105, 106, 108, 109, 110, 58, 59, 60, 62, 63, 64, 115, 116, 117, 119, 120, 121, 123, 124, 125, 127, 128, 129, 131, 132, 133.

The patent also claims that the antibody or its fragment can bind to the IgV domain of human hB7-H4 or the IgV domain of human and murine hB7-H4. Furthermore, the patent describes the antibody as a chimeric antibody, CDR-grafted antibody, humanized antibody, multispecific or bispecific antibody, or an IgG class immunoglobulin.

The patent also includes claims for a fusion protein comprising the anti-B7-H4 antibody or its fragment, an IL-15Ra sushi domain polypeptide, and an IL-15 polypeptide. The fusion protein can have specific sequences for the heavy chain CDRs (CDR1H, CDR2H, CDR3H) and the light chain CDRs (CDR1L, CDR2L, CDR3L), including combinations of SEQ ID NOs: 16, 17, 18, 70, 71, 72, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189.

The patent also covers methods of producing the anti-B7-H4 antibody, stimulating the immune system, treating cancer, and detecting B7-H4 in a sample using the antibody or its fragment. Additionally, the patent includes a nucleic acid sequence encoding the antibody, a cell comprising the nucleic acid, and a pharmaceutical composition containing the antibody and a carrier.

In summary, the patent describes an anti-B7-H4 antibody and its fragment with specific sequences for the heavy and light chain variable regions. It also covers various applications of the antibody, including fusion proteins, methods of production, immune stimulation, cancer treatment, and sample detection.

To know more about GlobalData’s detailed insights on Sanofi, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies